Healthcare Services

Acute Respiratory Distress Syndrome (ARDS) Market Expected To Witness Revenue Growth Toward $2.42 Billion By 2030

May 27, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Market Size Is Forecasted For The Acute Respiratory Distress Syndrome (ARDS) Market By 2030 Based On Its 2026 Value?

The market size for acute respiratory distress syndrome (ards) has expanded swiftly in recent years. Projections indicate it will increase from $1.41 billion in 2025 to $1.56 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.5%. Historically, this expansion can be attributed to the rising incidence of respiratory infections, growing hospital icu infrastructure, increasing awareness of ards management protocols, limited availability of advanced ventilation devices, and adoption of supportive care practices.

The acute respiratory distress syndrome (ARDS) market size is set to experience significant growth in the upcoming years. It is projected to reach $2.42 billion by 2030, with a compound annual growth rate (CAGR) of 11.7%. The expansion during this forecast period can be attributed to advancements in mechanical ventilation and ECMO systems, increasing research and development in ARDS therapeutics, the global proliferation of critical care units, rising investment in customized patient management solutions, and the growing incidence of severe pneumonia and sepsis. Major trends expected in the forecast period include a greater adoption of mechanical ventilation and ECMO devices, an increase in ARDS prevalence due to COVID-19 and other respiratory conditions, the expanding utilization of advanced diagnostic tests for early detection, an expansion of critical care and ICU facilities, and a focus on personalized and supportive care management.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13005&type=smp

What Core Drivers Are Transforming The Acute Respiratory Distress Syndrome (ARDS) Market?

The acute respiratory distress syndrome (ARDS) market is expected to witness growth moving forward due to the rising prevalence of respiratory illnesses. Respiratory illness refers to a variety of medical conditions that impact the respiratory system, including the airways and lungs, often resulting in breathing difficulties. The increased occurrence of respiratory illnesses, such as COVID-19, stands as a primary catalyst for the expansion of the acute respiratory distress syndrome (ARDS) market. As more individuals develop respiratory illnesses, the demand for ARDS treatments and therapies is anticipated to climb, fostering market growth. For instance, in October 2024, information from the National Asthma Council, an Australia-based non-profit organization, revealed that Australia recorded 474 asthma-related deaths in 2023, consisting of 325 females and 149 males. This figure is nearly identical to the 473 asthma-related deaths reported in 2022, indicating a consistent trend in asthma mortality over the two-year period. Thus, the escalating number of respiratory illnesses is propelling the growth of the acute respiratory distress syndrome (ARDS) market.

How Are Different Segment Groups Identified Within The Acute Respiratory Distress Syndrome (ARDS) Market?

The acute respiratory distress syndrome (ards) market covered in this report is segmented –

1) By Type: Diagnosis, Treatment

2) By Cause: COVID-19 Disease 2019 (COVID-19), Sepsis, Inhalation Of Harmful Substances, Severe Pneumonia, Other Causes

3) By Severity: Mild, Moderate, Severe

4) By End User: Hospitals, Clinics, Ambulatory Service Centers, Other End Users

Subsegments:

1) By Diagnosis: Imaging Tests, Blood Tests

2) By Treatment: Mechanical Ventilation, Medications, Extracorporeal Membrane Oxygenation (ECMO), Supportive Care

Which Trends Are Affecting The Acute Respiratory Distress Syndrome (ARDS) Market Framework?

Within the acute respiratory distress syndrome market, leading companies are concentrating on creating sophisticated immune modulators with the goal of improving patient survival rates and decreasing inflammation. These immune modulators function as treatments designed to restore the immune system’s equilibrium by addressing dysfunctional inflammatory pathways, all while avoiding the suppression of overall immune function. An illustrative example is BioAegis Therapeutics, a clinical-stage firm from the US, which in June 2025, secured FDA Fast Track designation for recombinant human plasma gelsolin (rhu-pGSN), its primary product intended for ARDS treatment. This particular therapy operates by restoring gelsolin, an essential immune regulatory protein, thereby modulating the activation of the NLRP3 inflammasome, boosting microbial clearance, eliminating harmful actin and inflammatory mediators, and regulating macrophage activity. Currently, rhu-pGSN is undergoing assessment in a global Phase 2b trial involving 600 patients suffering from moderate to severe ARDS, and it could also be accessible via the FDA Expanded Access or Compassionate Use program. Such Fast Track status facilitates quicker regulatory discussions, permits a rolling review process for marketing applications, and makes it eligible for priority review, which could potentially expedite its market entry and provide a new treatment choice for patients who have few other options.

Which Organizations Are Operating Within The Acute Respiratory Distress Syndrome (ARDS) Market?

Major companies operating in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline plc, Medtronic plc, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, Smiths Medical Inc., Dräger Safety AG & Co. KGaA, Getinge AB, Mallinckrodt plc, Masimo Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Windtree Therapeutics Inc., Faron Pharmaceuticals Oy

Access The Complete Acute Respiratory Distress Syndrome (ARDS) Market Report:

https://www.thebusinessresearchcompany.com/report/acute-respiratory-distress-syndrome-ards-global-market-report

Which Region Leads The Acute Respiratory Distress Syndrome (ARDS) Market By Size?

North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2025. The regions covered in the acute respiratory distress syndrome (ards) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Acute Respiratory Distress Syndrome (ARDS) Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=13005&type=smp

Browse Through More Reports Similar to the Global Acute Respiratory Distress Syndrome (ARDS) Market 2026, By The Business Research Company

Severe Acute Respiratory Syndrome Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/severe-acute-respiratory-syndrome-treatment-global-market-report

Respiratory Disease Testing Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-disease-testing-global-market-report

Acute Coronary Syndrome Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/acute-coronary-syndrome-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795